Elevation Oncology, Inc.
US ˙ NasdaqCM ˙ US28623U1016
QUESTO SIMBOLO NON E' PIU' ATTIVO

SecurityELEV / Elevation Oncology, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership2,610,045 shares
Ownership 4.41%
Vanguard Group Inc ownership in ELEV / Elevation Oncology, Inc.

2025-01-30 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,610,045 shares of Elevation Oncology, Inc. (US:ELEV). This represents 4.41 percent ownership of the company. In their previous filing dated 2024-11-12 , Vanguard Group Inc had reported owning 3,071,580 shares, indicating a decrease of -15.03 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-01-30 2025-01-30 13G/A 3,071,580 2,610,045 -15.03 4.41 -15.03
2024-11-12 2024-11-12 13G/A 3,071,580 3,071,580 0.00 5.19 0.00
2024-11-04 2024-11-04 13G/A 3,071,580 5.19

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-11-07 2025-09-30 13F ELEVATION ONCOLOGY COM 28623U101 0 -100.00 0
2025-08-11 2025-06-30 13F ELEVATION ONCOLOGY COM 28623U101 2,256,690 -328,530 -12.71 828 23.77 0.0000
2025-05-09 2025-03-31 13F ELEVATION ONCOLOGY COM 28623U101 2,585,220 -24,825 -0.95 670 -54.46 0.0000
2025-02-11 2024-12-31 13F ELEVATION ONCOLOGY COM 28623U101 2,610,045 -461,535 -15.03 1,469 -20.25 0.0000
2024-11-13 2024-09-30 13F ELEVATION ONCOLOGY COM 28623U101 3,071,580 1,154,537 60.22 1,843 -64.41 0.0000
2024-08-13 2024-06-30 13F ELEVATION ONCOLOGY COM 28623U101 1,917,043 384,998 25.13 5,176 -34.14 0.0001
2024-05-10 2024-03-31 13F ELEVATION ONCOLOGY COM 28623U101 1,532,045 360,799 30.80 7,859 1,151.43 0.0002
2024-03-11 2023-12-31 13F/A-1 ELEVATION ONCOLOGY COM 28623U101 1,171,246 101,441 9.48 629 -11.30 0.0000
2024-02-14 2023-12-31 13F ELEVATION ONCOLOGY COM 28623U101 1,171,246 101,441 629 0.0000
2023-12-18 2023-09-30 13F/A-1 ELEVATION ONCOLOGY COM 28623U101 1,069,805 -5,352 -0.50 709 -56.67 0.0000
2023-11-14 2023-09-30 13F ELEVATION ONCOLOGY COM 28623U101 1,069,805 -5,352 709 0.0000
2023-08-14 2023-06-30 13F ELEVATION ONCOLOGY COM 28623U101 1,075,157 619,376 135.89 1,634 88.90 0.0000
2023-07-14 2023-03-31 13F/A-1 ELEVATION ONCOLOGY COM 28623U101 455,781 122,473 36.74 866 173.73 0.0000
2023-05-15 2023-03-31 13F ELEVATION ONCOLOGY COM 28623U101 455,781 122,473 866 0.0000
2023-02-10 2022-12-31 13F ELEVATION ONCOLOGY COM 28623U101 333,308 284 0.09 317 -15.96 0.0000
2022-11-14 2022-09-30 13F ELEVATION ONCOLOGY COM 28623U101 333,024 -67,829 -16.92 376 -32.98 0.0000
2022-08-12 2022-06-30 13F ELEVATION ONCOLOGY COM 28623U101 400,853 24,700 6.57 561 -40.82 0.0000
2022-05-13 2022-03-31 13F ELEVATION ONCOLOGY COM 28623U101 376,153 -4,660 -1.22 948 -58.64 0.0000
2022-02-14 2021-12-31 13F ELEVATION ONCOLOGY COM 28623U101 380,813 -274,596 -41.90 2,292 -55.11 0.0001
2021-11-12 2021-09-30 13F ELEVATION ONCOLOGY COM 28623U101 655,409 595,409 992.35 5,106 527.27 0.0001
2021-08-13 2021-06-30 13F ELEVATION ONCOLOGY COM 28623U101 60,000 60,000 814 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.